<?xml version="1.0" ?>
<doc>
	<str name="Patent Number">
		US7368542
	</str>
	<str name="Application Number">
		US10863365
	</str>
	<str name="Kind Code">
		B2
	</str>
	<str name="Title">
		Method of altering the binding specificity of plasma proteins by oxidation-reduction reactions
	</str>
	<str name="Abstract">
		The binding specificity of at least one plasma protein suspended or dissolved in a liquid medium is altered by exposing the protein to an oxidizing agent or an electric current sufficient to alter its binding specificity. A masked protein such as an autoantibody can be recovered from blood or blood products or extracts by oxidizing the protein to change its binding specificity.
	</str>
	<str name="Document Types">
		US | USB | DOCDB
	</str>
	<str name="Application Date">
		2004-06-09
	</str>
	<str name="Application Year">
		2004
	</str>
	<str name="Application(Year/Month)">
		2004-06
	</str>
	<str name="Publication Date">
		2008-05-06
	</str>
	<str name="Publication Year">
		2008
	</str>
	<str name="Publication(Year/Month)">
		2008-05
	</str>
	<str name="All IPC">
		C07K16/00 | G01N33/564 | A61K39/395
	</str>
	<str name="IPC Primary">
		C07K16/00
	</str>
	<str name="IPC Section">
		C
	</str>
	<str name="IPC Class">
		C07
	</str>
	<str name="IPC Subclass">
		C07K
	</str>
	<str name="IPC Group">
		C07K16
	</str>
	<str name="All UPC">
		530/390.5 | 530/387.1 | 530/390.1 | 424/176.1 | 530/402 | 436/825 | 424/810 | 210/758 | 530/868 | 424/177.1 | 530/427 | 436/506 | 204/554
	</str>
	<str name="UPC Primary">
		530/390.5
	</str>
	<str name="UPC Class">
		530
	</str>
	<str name="Family Members">
		US20050101016A1 | US7368542
	</str>
	<str name="Family Member Count">
		2
	</str>
	<str name="Family Members Cited By Count">
		1
	</str>
	<str name="Other References">
		McIntyre, John A., &quot;The Appearance and Disappearance of Antiphospholipid Autoantibodies Subsequent to Oxidation-reduction Reactions&quot;, Thrombosis Research 2004, 114, pp. 579-587. cited by other . | Martinez-Cordero et al., J. Invest Allerg Clin Immunol 7, 1997, pp. 596-601. cited by other. | Jedryka-Goral. Et al. Clin Rheumatol 19, 2000, pp. 306-310. cited by other . | www.ucsfhealth.org/childrens/edu/bottleWeaning.html , provided by UCSF Children's Hospital, Patient Education, Baby Bottle Weaning, 2002-2007. cited by other . | Gomez-Puerta et al., Rheumatol 44:, 2005, pp. 95-99. cited by other . | Smith, Mark A., et al, &quot;Widespread Peroxynitrite-Mediated Damage in Alzheimer's Disease&quot;. J. Neuroscience, Apr. 15, 1997, 17(8), pp. 2653-2657. cited by other . | Chapman, J. et al, &quot;Antiphospholipid Antibodies Permeablizie and Depolarize Brain Synaptoneurosomes&quot;, Lupus 1999; 8: pp. 127-133. cited by other . | D'Aandrea, PhD, Michael R., &quot;Evidence that immunoglobulin-positive Neurons in Alzheimer's Disease are Dying Via the Classical Antibody-dependent Complement Pathway&quot;, Am. J. Alzheimer's Dis. Other Dimentas 2005; 20; pp. 144-150. cited by other . | Sokol, D.K. et al, &quot;Testing for Antiphospholipid Antibody (aPL) Specificities in Retrospective `Normal` Cerebral Spinal Fluid (CSF)&quot;, Clin Develop. Immunol. 2005; 11: pp. 7-12. cited by other . | Hindley, Alison et al, &quot;Extracellular Signal Regulated Kinase (ERK)/mitogen Activated Protein Kinase (MAPK)-independent Functions of Raf Kinases&quot;, J. Cell Science, 2002; 115, pp. 1575-1581. cited by other . | Ischiropoulus, Harry et al, &quot;Oxidative Stress and Nitration in Neurodegeneration: Cause, effect, or association?&quot;, J. Clin. Invest. 2003 111:pp. 163-169. cited by other . | Sokol et al., Nuerology 55: 2000, pp. 1379-1381. cited by other . | Robertson and Greaves, Blood Rev 20: 2006, pp. 201-212. cited by other . | McIntyre, John A., &quot;The appearance and Disappearance of Antiphospholipid Antibodies Subsequent to Oxidation-Reduction Reactions&quot;, appearing in Thrombosis Research, 2004, vol. 114, pp. 579-. cited by other . | Mosek et al. Dem. Ger Cog. Disorder 11:, 2000, pp. 36-38. cited by other . | Colucci-D'Amato, L. et al, &quot;Chronic-Activation of ERK and Neurodegenerative Diseases&quot;, Bioassays, 2003; 25; pp. 1085-1095. cited by other . | McIntyre, John A., et al, &quot;Autoantibodies Unmasked by Redox Recations&quot;, J. Autoimmun 2005; 24, pp. 311-317. cited by other . | Adams, J. Paige et al, &quot;Molecular Psychology: Roles for the ERK MAP Kinase Cascade in Memory&quot;, Annu. Rev. Pharmacol. Toxicol. 2002, 42, pp. 135-163. cited by other . | Gallo et al., J. Neurol Sc. 122, 1994, pp. 97-101. cited by other . | McIntyre, John A., et al &quot;Redox-reactive Autoantibodies: Detection and Physiological Relevance&quot;, Autoimmunity Reviews 2006; 5, pp. 76-83. cited by other . | Tanne et al., Curr Rheumat Rep 3, 2001, pp. 286-292. cited by other . | Cheung et al, &quot;Emerging Role for ERK as a Key Regulator of Neuronal Apoptosis&quot;, Science, 2004; 251: pp. 1-3. cited by other . | Oomen et al. Psychiat Res 58, 1995, pp. 83-88. cited by other .
	</str>
	<str name="Other References Count">
		23
	</str>
	<str name="Cited By">
		US8334146
	</str>
	<str name="Cited By Count">
		1
	</str>
	<str name="Cites">
		US4950612 | US5061790 | US5939394 | US20050101016 | US4703001 | US5980954 | US20040101909 | US6660267 | WO2004111608
	</str>
	<str name="Cites Count">
		9
	</str>
	<str name="Priority Country">
		US | US
	</str>
	<str name="Priority Number">
		86336504 | 47660703
	</str>
	<str name="Priority Date">
		2004-06-09 | 2003-06-09
	</str>
	<str name="Assignee(s)">
		REDOX-REACTIVE REAGENTS LLC
	</str>
	<str name="1st Assignee">
		REDOX-REACTIVE REAGENTS LLC
	</str>
	<str name="Number of Assignees">
		1
	</str>
	<str name="1st Assignee Address">
		Beech Grove, IN
	</str>
	<str name="Assignee(s) Address">
		Beech Grove, IN
	</str>
	<str name="Inventor(s)">
		MCINTYRE, JOHN, A.
	</str>
	<str name="1st Inventor">
		MCINTYRE, JOHN, A.
	</str>
	<str name="Number of Inventors">
		1
	</str>
	<str name="1st Inventor Address">
		Indianapolis, IN
	</str>
	<str name="Inventor(s) Address">
		Indianapolis, IN
	</str>
	<str name="Agent/Attorney">
		ANTONELLI, TERRY, STOUT &amp; KRAUS, LLP.
	</str>
	<str name="Primary Examiner">
		SAUNDERS, DAVID A.
	</str>
	<str name="cited by within 3 years">
		0
	</str>
	<str name="cited by within 5 years">
		0
	</str>
</doc>

